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Abstract
Background: Highly pathogenic avian influenza virus (HPAIV) causes a highly contagious often fatal disease in poultry,
resulting in significant economic losses in the poultry industry. HPAIV H5N1 also poses a major public health threat as it can
be transmitted directly from infected poultry to humans. One effective way to combat avian influenza with pandemic
potential is through the vaccination of poultry. Several live vaccines based on attenuated Newcastle disease virus (NDV) that
express influenza hemagglutinin (HA) have been developed to protect chickens or mammalian species against HPAIV.
However, the zoonotic potential of NDV raises safety concerns regarding the use of live NDV recombinants, as the
incorporation of a heterologous attachment protein may result in the generation of NDV with altered tropism and/or
pathogenicity.
Methodology/Principal Findings: In the present study we generated recombinant NDVs expressing either full length,
membrane-anchored HA of the H5 subtype (NDV-H5) or a soluble trimeric form thereof (NDV-sH53). A single intramuscular
immunization with NDV-sH53 or NDV-H5 fully protected chickens against disease after a lethal challenge with H5N1 and
reduced levels of virus shedding in tracheal and cloacal swabs. NDV-sH53 was less protective than NDV-H5 (50% vs 80%
protection) when administered via the respiratory tract. The NDV-sH53 was ineffective in mice, regardless of whether
administered oculonasally or intramuscularly. In this species, NDV-H5 induced protective immunity against HPAIV H5N1, but
only after oculonasal administration, despite the poor H5-specific serum antibody response it elicited.
Conclusions/Significance: Although NDV expressing membrane anchored H5 in general provided better protection than its
counterpart expressing soluble H5, chickens could be fully protected against a lethal challenge with H5N1 by using the
latter NDV vector. This study thus provides proof of concept for the use of recombinant vector vaccines expressing a soluble
form of a heterologous viral membrane protein. Such vectors may be advantageous as they preclude the incorporation of
heterologous membrane proteins into the viral vector particles.
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Introduction
Highly pathogenic (HP) avian influenza viruses (AIVs) are the
cause of bird flu (also called fowl plague), a highly contagious and
often fatal disease of poultry. The HPAIV of the H5N1 subtype
that emerged in Southern China in 1996 has continued to
circulate in domestic poultry to date. In addition, there are
concerns about the pandemic potential of H5N1 HPAIV, as
hundreds of people have been infected, of which approximately
60% succumbed to the infection. One effective way to combat
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avian influenza with pandemic potential is through the vaccination
of poultry. Conventional, inactivated influenza vaccines must be
administered individually and often require a boost vaccination to
induce protective immunity. The administration of these vaccines
is thus not only time-consuming, laborious and expensive, but may
also increase the risk of exposure of people involved to circulating
influenza virus. Live vaccines, which elicit both humoral and
cellular immune responses, in general provide rapid protection
after a single dose. Another advantage of live vaccines is that they
do not need to be adjuvant-formulated, thereby limiting produc-
tion costs. Because the use of live influenza vaccines has obvious
safety restrictions, alternative vaccines based on different heterol-
ogous viral vectors have been developed, including pox virus [1],
adenovirus [2], infectious laryngotracheitis virus [3], baculovirus
[4] and Newcastle disease virus (NDV) [5–11].
NDV is an enveloped virus with a negative-strand, nonseg-
mented RNA genome that belongs to the Paramyxoviridae family
[12]. It is an important pathogen of poultry sometimes causing
high rates of mortality depending on the virulence of the infecting
strain. Live attenuated, lentogenic NDV strains are used in many
countries for vaccination of commercial poultry against infection
with virulent, velogenic NDV. The use of lentogenic NDV vectors
that express AIV hemagglutinin (HA) genes may be an attractive
approach to vaccinate against influenza, as antibodies against HA
protect against AIV infection and disease. Indeed, an increasing
number of studies has shown that NDV can be successfully used as
a vaccine vector for delivery of HA antigen to protect chickens
[7,8] and mammals [5,6] against influenza. In poultry, such a
vaccine does not only protect against influenza virus but also
against NDV infection [5,9–11]. Furthermore, it allows serological
differentiation of infected from vaccinated animals (DIVA
principle) [11,13].
NDV has a wide tissue/host tropism and can infect various
mammalian species in addition to birds [14]. While this
characteristic makes NDV a suitable vaccine vector for use in
other animals than birds, also humans are among the many species
that can be infected with NDV. Infection with NDV is seen most
often in people who have been in contact with high doses of virus,
as for instance members of vaccination teams performing
vaccination with NDV aerosols. Infected people manifest signs
of conjunctivitis for a few days and are protected on re-exposure
[15]. However, the zoonotic potential of NDV has raised safety
concerns regarding the use of live NDV recombinants as vector
vaccines. Furthermore, insertion of genes encoding heterologous
viral attachment/fusion proteins into the NDV genome, may
result in the incorporation of these proteins into the viral envelope
and hence in the generation of NDV with altered tropism and/or
pathogenicity. Full length HA protein expressed by NDV was
indeed shown to be incorporated into NDV particles [7,11,16],
although a change in tropism or increased virulence was not
observed [16]. Although expressed foreign proteins in nonseg-
mented negative-strand RNA virus in general do not appear to
enhance the virulence of the vector or shift its tropism [17,18], one
must confirm this for each vector/insert combination, using both
avian and mammalian experimental species [19]. As such safety
issues cannot be completely ruled out, the design of alternative
approaches, in which NDV is used as a vector vaccine, is
warranted.
In a previous study, we demonstrated the vaccine potential of
recombinant soluble trimeric subtype 5 hemagglutinin (sH53)
produced in mammalian cells [20]. The sH53, which lacks a
transmembrane anchor and is therefore secreted from cells, is
biologically active as demonstrated by its binding to sialic acid
receptors. A single intramuscular vaccination with adjuvanted
sH53 antigen conferred complete protection to chickens against a
lethal challenge with HPAIV H5N1, whereas mice required a
boost immunization for complete protection. The efficacy of the
recombinant soluble HA vaccination approach has also been
demonstrated using other HA subtypes and different animal
models [21–23].
In the present study, we modified the genome of NDV strain
Herts/33 to generate NDV-sH53, an attenuated NDV vector
expressing the soluble trimeric form of H5. As this protein lacks a
transmembrane domain, it is not anchored into cellular mem-
branes and hence no NDV virions carrying HA proteins are
produced. This approach therefore diminishes the risk of
generating a recombinant NDV with altered tropism or increased
pathogenicity, resulting from incorporation of heterologous
attachment proteins into virions. We examined the ability of this
recombinant NDV to induce protection against a lethal H5N1
infection in chickens and mice in comparison to a recombinant
NDV expressing the full length H5 protein (NDV-H5). Vaccina-
tion of chickens with NDV-sH53 by the intramuscular (IM) route
was shown to provide complete protection against a lethal
challenge with HPAIV H5N1. However, mucosal immunization
reduced vaccine efficacy in comparison with the IM route. The
NDV-sH53 vaccine appeared to be ineffective in mice, although in
this species the NDV-H5 induced protective immunity after
combined ocular and intranasal administration.
Materials and Methods
Cells and viruses
Quail muscle (QM5) cells [24] were cultured in QT35 complete
medium (Life Technology), supplemented with 5% fetal bovine
serum (FBS) and antibiotics. NDV strain Herts/33 was propagated
by inoculation into the allantoic cavity of 9 to 11-day-old
embryonated specific pathogen-free (SPF) chicken eggs. Allantoic
fluid was harvested after 3 days, clarified and aliquoted.
Recombinant fowlpox virus fpEFLT7 (herein called FPV-T7),
providing stable expression of bacteriophage T7 RNA polymerase
in both avian and mammalian cells [25], was propagated in
primary chicken embryo liver cells (prepared in the laboratory of
the Central Veterinary Institute). HPAIV A/Vietnam/1194/04
H5N1 (kindly provided by Dr. Alan Hay from the WHO
Influenza Centre at the National Institute for Medical Research,
London) was propagated in 9 to 11-day-old embryonated SPF
chicken eggs to produce a virus stock. All experiments with
HPAIV, including animal studies, were conducted under BSL3
conditions.
Construction of NDV cDNAs expressing the HA protein of
H5N1 influenza virus
The construction of full-length cDNA of NDV Herts/33, pFL-
HertsAF, in which the F gene is flanked by the unique restriction sites
AscI and FseI, has been described before [26]. In order to generate an
attenuated NDV, the polybasic cleavage site of the fusion (F) protein
was modified into a monobasic cleavage motif (GRQGRQL;
creating FDPBC). To this end, the F gene from pFL-HertsAF was
amplified by overlap extension (OE)-PCR using primer pair
pAscI(Herts) (59-TTGGCGCGCCCCAGGTGCAAGATGGGC-
39; AscI underlined) and N043 (59-TTACTAGTTTACGAAAAG-
TATTGGATTTGTGCCCC-39), and N044 (59-GGAGGGAGA-
CAGGGACGCCTTATAGGTGCCATTATCG-39) and pFseI(-
Herts) (59-CCCGATTGAGGGCCGGCCTCCCC-39; FseI
underlined). Both PCR products were added as template in a
second PCR using only the flanking primers pAscI(Herts) and
pFseI(Herts) to fuse both fragments. The obtained PCR product was
Recombinant NDV Expressing Soluble HA Vaccine
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cloned between the AscI and FseI site of pFL-HertsAF, generating
pFL-HertsDPBC. For insertion of the H5 genes between the P and
M genes, XbaI and PmeI restriction sites were created in the P-M
intergenic region of pFL-HertsDPBC by OE-PCR. First, cDNA of
the pFL-HertsDPBC was amplified with primer pair pMT7 (59-
GTGCTAACGTTTCTTCTCTAAGTGATC-39; AclI underlined)
and pMT6 59-GTTTAAAGCGAGTTGCGCGATCATCTA-
GAGGGGTAG-39; XbaI site underlined) and primer pair pMT5
(59-TCTAGATGATCGCGCAACTGCGTTTAAACTAGCAG
C-39; PmeI underlined) and pMT8 (59-CACTTCCTAGGCA-
GAGCATCGCAGAGG-39; AvrII underlined). The overlapping
PCR products were then fused by PCR performed with the
flanking primers pMT7 and pMT8. The resulting PCR fragment
was cloned between the AclI and AvrII site of pFL-HertsDPBC.
Subsequently, a synthetic linker (59-GCTCTAGATAAGAAAAAA-
TACGGGTAGAA GTTTAAACGGCGCGCCGG-39) containing
the sequence of the NDV transcription termination and start
signals (italics) and XbaI and PmeI sites (underlined) was inserted
using the XbaI and PmeI sites, resulting in pFL-HertsXP+DPBC.
The H5N1 A/Vietnam/1194/2004 virus (GenBank accession
no. ABW90137.1), lacking a multibasic cleavage site in the H5
protein, was used as the source of the HA gene. Viral RNA was
extracted from the virus using a High Pure Viral RNA kit (Roche)
and reverse transcribed using Superscript II (Invitrogen) and
primer 59-AGCAAAAGCAGG-39, matching the non-coding
region of each segment. The HA gene was amplified with primers
59-AGCTTTGTTTAAACAATGGAGAAAATAGTGCTTC T
TTTTGC-39 (start codon in bold) and 59-CCGGCGC
GCCGTTTAAACTTAAAT GCAAATTCTGCATTGTAAC-
39 (stop codon in bold) each containing a PmeI site (underlined).
The PCR product was digested with PmeI and inserted into pFL-
HertsXP+DPBC constructed in the previous step using the created
PmeI site, resulting in pFL-HertsDPBC-H5.
To create pFL-HertsDPBC-sH53, the pCD5-sH53 expression
vector was used [20]. This vector encodes the predicted HA
ectodomain from A/Vietnam/1194/2004 under the control of a
CMV promoter. The H5 sequence is preceded by a CD5 signal
peptide-encoding sequence and followed by sequences coding for
the GCN4 isoleucine-zipper trimerization motif [27] and the
Strep-Tag II (IBA, Germany). In addition, this construct contains
PmeI restriction sites upstream of the signal peptide and
downstream of the Strep-Tag II coding sequences. The pCD5-
sH53 plasmid was digested with PmeI and the liberated insert was
ligated into similarly digested pFL-HertsXP+DPBC, resulting in
pFL-HertsDPBC-sH53. Each pFL-Herts construct was generated
as such that the size of the genome complied with ‘‘the rule of six’’
[28,29]. All plasmids were cloned according to standard proce-
dures and sequence analysis was performed to verify that no
inadvertent changes had been introduced.
Rescue of recombinant NDV
Recombinant NDV was generated by reverse genetics using the
FPV-T7 RNA polymerase system essentially as described previ-
ously [30]. Briefly, QM5 cells grown to subconfluency in 6-well
dishes were infected with FPV-T7 and transfected with the full-
length cDNA and helper plasmids expressing the NDV replication
proteins NP, P and L. The supernatant was harvested after 6 days
of incubation at 37uC and inoculated (0.2 ml) into the allantoic
cavity of embryonated SPF chicken eggs. After incubation for 3
days, the allantoic fluid was clarified, diluted in PBS (1:1000) and
filtered through a 0.2 mm pore filter to remove FPV-T7. The
filtrate was then inoculated into the allantoic cavity of embryo-
nated SPF chicken eggs to amplify the virus. Allantoic fluid was
harvested after 3 days, clarified and aliquoted. Virus recovered
from pFL-HertsDPBC-H5 was designated NDV-H5 and virus
recovered from pFL-HertsDPBC-sH53 was designated NDV-
sH53. Virus titers (TCID50 ml
21) of the harvests were determined
in QM5 cells by the end-point dilution method reading CPE at
5 days post infection (p.i.). and calculated according to Reed and
Mu¨nch [31].
Intracellular immunoperoxidase staining and western
blot analysis
Expression of the HA protein in QM5 cells after infection with
recombinant NDV was analyzed by intracellular immunoperox-
idase staining as described [32]. For this, the cells were
permeabilized, fixed with 4% paraformaldehyde and incubated
with monoclonal antibody (mAb) 15A6 anti-H5 (1:500; Santa
Cruz). Anti-F mAb 8E12A8C3 (1:5000; CVI, Lelystad) was used
for detection of the F protein as control for NDV replication.
Horse radish peroxidase-conjugated rabbit-anti-mouse immuno-
globulin (1:1500; Dako P0260) was used as the secondary
antibody. Binding of this antibody was detected using 3-amino-
9-ethylcarbazole (AEC) peroxidase substrate (Sigma), enzymatic
conversion of which produces a red reaction product. HA protein
expression by recombinant NDV was confirmed by sodium
dodecylsulfate (SDS)-polyacrylamide gel electrophoresis (PAGE)
followed by western blotting. At 64 h p.i., combined lysates were
prepared of the cell culture media and cells using Passive Lysis
Buffer (Promega). Proteins in the lysates were separated by SDS-
PAGE, transferred onto an InvitrolonTM PVDF filter (Invitrogen)
and probed with the anti-H5 mAb. Binding of the second
peroxidase-conjugated anti-mouse antibody (Dako P0260) was
visualized by chemiluminescence using the Supersignal kit (Pierce).
Production and purification of sH53
For the production of recombinant sH53 protein, QM5 cells
were infected with NDV-sH53 diluted in trypsin-free DMEM at a
multiplicity of infection (moi) of 3 TCID50 units per cell. Tissue
culture supernatants were collected (10 ml) after 72 h of incuba-
tion at 37uC and subsequently clarified by low-speed centrifuga-
tion. The pH of the harvest was adjusted to 7.8 and Avidin (IBA,
Germany) was added until a final concentration of 3 mg ml21.
After 4 h, recombinant sH53 protein was purified using Strep-
Tactin sepharose beads as described by the manufacturer (IBA,
Germany). The sH53 protein concentration was determined with a
nano-drop spectrophotometer and estimated on gel using a series
of known amounts of bovine serum albumin (BSA) as reference.
To this end, the purified sH53 and the BSA samples were
subjected to SDS-PAGE after which proteins were stained with
Blue stain reagent (Thermo Scientific). The oligomerization status
of the sH53 protein was determined by blue native-PAGE analysis
followed by western blotting as described above using a mAb anti-
Strep-tag (IBA, Germany).
Intracerebral pathogenicity index
All animal experiments were conducted in the high containment
facility of the Central Veterinary Institute. The standardized
chicken pathogenicity test was performed as described in the
European Community Council Directive 92/66/EEC [33].
Briefly, 10 one-day-old SPF chickens (Lohmann, Germany) were
injected intracerebrally with 0.05 ml of a 1/10 dilution of the egg-
grown HertsDPBC virus and observed for clinical signs every day
over a period of 8 days. The birds received a score of 0 if they
appeared normal, 1 if they were sick, and 2 if they were dead. The
intracerebral pathogenicity index (ICPI) was calculated as the
mean score per bird per observation.
Recombinant NDV Expressing Soluble HA Vaccine
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Vaccination experiment in chickens
SPF White Leghorn chickens (Lohmann, Germany) of 6 weeks
old were used in this experiment. Groups of 10 chickens were
vaccinated with 107 TCID50 of vaccine virus either by the IM
(0.5 ml) or the combined oculonasal/ intratracheal (ON/IT;
0.2 ml) route. In addition, one group of 10 chickens was
vaccinated IM with 5 mg of recombinant sH53 protein
adjuvanted with Stimune (Prionics, [34]). Another group of ten
chickens received PBS ON/IT as well as PBS in Stimune IM to
serve as mock-vaccinated control for each administration route.
The experimental groups were housed in separate rooms. In
each group, two sentinels were housed together with the test
animals (from day one p.v. onwards). All birds were challenged
3 weeks post vaccination (p.v.) by intranasal (0.1 ml) and
intratracheal (0.1 ml) inoculation of in total 105 TCID50 of
H5N1 HPAIV A/Vietnam/1194/04. The chickens were daily
inspected for signs of disease during the entire experimental
period. Observations of clinical signs and mortality post
challenge (p.c.) were recorded for 10 days according to the
following scoring system: 0 = healthy, 1 = sick, 2 = severely ill,
and 3 = dead. Chickens were inspected twice a day as long as
severe illness (score of 2) was scored. Birds that were reluctant to
move in response to manipulation or unable to reach the feeding
and water bin were euthanized. The clinical index was
calculated as the mean score per bird per observation. Blood
samples were collected at 3 weeks after immunization. Tracheal
and cloacal swabs were taken on day 2, 4 and 7 p.c in order to
assess shedding of challenge virus.
Vaccination experiment in mice
Female, 7-week-old BALB/c mice (SPF; Charles River Labo-
ratories, Germany) were allocated to 5 experimental groups with
10 animals each. For vaccination, mice were anaesthetized with
ketamin/xylazine intraperitoneally and inoculated oculonasally
(ON; 50 ml) or IM (50 ml in each hind leg) with 106.5 TCID50 of
vaccine virus. As challenge control, one group of mice received
PBS ON (50 ml) and PBS in Stimune IM (100 ml). Three weeks
after vaccination, mice were anaesthetized as described above and
infected intranasally (50 ml) with 10 times the 50% lethal dose
(LD50) of the homologous H5N1 A/Vietnam/1194/04 virus.
Mice were weighed and observed daily for signs of disease for the
next 14 days. Clinical signs were scored on a scale of 0 to 4,
wherein 0= no clinical signs; 1 = rough coat; 2 = rough coat, less
reactive, passive during handling; 3 = rough coat, rolled up,
laboured breathing, passive during handling; 4 = rough coat,
rolled up, laboured breathing, inactive in response to manipula-
tion/ handlings. Mice were inspected twice a day as long as they
received a score of 3 and were euthanized when they received a
score of 4. Blood samples were collected at 3 weeks after the
immunization. Surviving animals were bled and sacrificed on day
14 p.c.
Ethics statement
All animal studies were performed in accordance with the
Dutch Law on Animal Experiments (Wod, ID number
BWBR0003081). The study protocols were approved by the
Animal Ethics Committee of the Central Veterinary Institute of
the Wageningen UR (Permit Numbers: 2009011, 2010006 and
2010119). Chicken embryos (14 days of age) used for the
collection of liver tissue were humanely euthanized by
decapitation. Embryonated eggs used in the propagation of
virus were cooled at 4uC for at least 4 h prior to harvest of
allantoic fluid.
Viral RNA detection by real time RT-PCR
Viral RNA was extracted from 0.2 ml of pooled tracheal and
cloacal swabs collected from each bird on the particular sampling
days. The amount of viral RNA was analyzed by real-time RT-
PCR amplifying the M1 gene of influenza A virus [35] similarly as
described before [20], this time using a Mx3005p thermocycler
(Agilent Technologies). Viral RNA present in serial 10-fold
dilutions of H5N1 A/Vietnam/1194/04 with known virus titer
was analyzed in parallel to generate a standard curve for
correlation of cycle threshold (CT) values with virus infectivity
titers. As control for cross-over contamination, negative samples
(PBS) were included at random positions on the test plates.
Serum antibody detection
Heat-inactivated immune sera from chicken blood samples were
tested in two-fold serial dilutions for hemagglutination inhibition
(HI) activity with 1% chicken red blood cells and 4 hemaggluti-
nating units (HAU) of the particular virus. Immune sera prepared
from mouse blood samples were treated O/N with Vibrio Cholera
derived neuraminidase (Roche), heat-inactivated at 56uC for 30
min and tested by HI assay using turkey red blood cells as
described above. Antibody titers were expressed as the reciprocal
of the highest serum dilution showing HI.
Results
Generation of NDV-H5 and NDV-sH53 recombinant
viruses and expression of HA proteins
The cleavage site of the NDV F protein is an important
determinant of virulence in chickens [30,36]. Velogenic strains,
including Herts/33, typically contain F proteins with multibasic
cleavage sites, which are cleaved by furin-like proteases, and have an
ICPI of 1.2 to 2.0. In contrast, lentogenic viruses contain F proteins
with a single basic amino acid andhave an ICPI of 0.7 or less [14,36].
In order to generate an attenuated virus, the full-length cDNA clone
of Herts/33 was modified such that the encoded F protein had a
monobasic cleavage motif (pFL-HertsDPBC). Intracerebral inocu-
lation with virus recovered from pFL-HertsDPBC resulted in an
ICPI of 0.04, indicating that this virus is indeed low-pathogenic to
chickens.
Next, we generated two NDV recombinant viruses, NDV-H5
and NDV-sH53, expressing either the full length HA (H5) or a
soluble trimeric form (sH53) of the HA protein, respectively.
Previously Wei and coworkers [37] have shown that soluble
trimeric HA proteins are superior antigens when compared to
their monomeric counterparts. The H5 encoding sequences were
each inserted between the P and M genes of the pFL-HertsDPBC
vector (Fig. 1A). For proper expression, the HA genes were flanked
by NDV transcription start and termination signals. The
recombinant NDV-H5 and NDV-sH53 could be readily recovered
after transfection of the full-length constructs into QM5 cells. Both
viruses replicated to high titers in embryonated chicken eggs;
NDV-H5 and NDV-sH53 yielded a titer of 8.0 log10 and 8.5 log10
TCID50 ml
21, respectively. NDV-H5 and NDV-sH53 both had an
ICPI value of 0.00. RT-PCR performed on the allantoic fluid and
subsequent sequencing of the PCR products confirmed the
presence of the proper H5-encoding inserts in the viral genomes.
To verify expression of the HA proteins during infection, QM5
cells were infected with egg-cultured wild type (wt) NDV(Herts/33),
NDV-H5 or NDV-sH53 or they were mock-infected. At day 5 p.i.,
they were subjected to immunocytochemistry usingmAb specific for
NDV F- or influenza virus H5. The results show that many cells in
the monolayer were infected with wt NDV or the recombinant
NDVs, while no F protein could be detected after mock infection
Recombinant NDV Expressing Soluble HA Vaccine
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Figure 1. Construction of recombinant NDV, expression and purification of H5 protein. A) Construction of pFL-HertsDPBC expressing
influenza H5N1 HA proteins. The sequence of the full-lenght cDNA of Herts/33, which codes for the multibasic cleavage site of the F protein was
mutated into a monobasic cleavage site-encoding sequence (FDPBC) resulting in pFL-HertsDPBC. The HA gene of H5N1 A/Vietnam/1194/04,
encoding either the full length or the soluble trimeric form, was cloned between the PmeI sites created in the intergenic region of the P and M genes
of the pFL-HertsDPBC vector following insertion of a linker containing NDV transcription termination and start signals. NP, nucleoprotein; P,
phosphoprotein; M, membrane protein; F, fusion protein; HN, hemagglutinin-neuraminidase; L, large polymerase. B) Expression of HA protein by
recombinant NDV in QM5 cells. Cells were infected with wt NDV (Herts/33), NDV-H5, NDV-sH53 or were mock-infected and analyzed by
Recombinant NDV Expressing Soluble HA Vaccine
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(Fig. 1B). In addition, similar numbers of cells were positive for the
H5 protein when cells had been infected with NDV-H5 and NDV-
sH53. Less intense staining was observed for cells infected with
NDV-sH53 relative to the NDV-H5-infected cells, presumably
because the sH53 protein does not accumulate in the cells but is
secreted into the cell culture medium. No H5-specific staining was
observed in cells infected with wt NDV. The HA protein expression
levels were further analyzed by subjecting from each infection a
sample of the combinedQM5cell lysate and cell culture supernatant
to SDS-PAGE analysis followed by western blot using an anti-H5
mAb. As expected, proteins with an apparent molecular weight of
,70 kDa, corresponding to either the uncleaved full length H5
protein or the solubleH5 protein containing the trimerizationmotif,
were detected after infection with the recombinant NDVs but not
after infection with the wt NDV (Fig. 1C). It appeared that the sH53
protein reached a,3 fold higher expression level than its full length
counterpart. The recombinant sH53 protein was purified from the
supernatant of NDV-sH53-infected QM5 cells by making use of the
StrepTag. Blue stain SDS-PAGEanalysis of the purification product
again revealed a,70 kDa protein with an estimated yield of 0.9 mg
per 100 ml of cell culture medium based on a series of known
amounts of BSA that were run in the same gel (Fig. 1D). To confirm
its oligomeric nature, the purified sH53 protein was subjected to
blue-native gel electrophoresis (Fig. 1E). When the H5 preparation
was heat-denatured for increasing time periods prior to electropho-
resis, the initially oligomeric HA species, presumably corresponding
to trimers based on previous results [20], dissociated intomonomers.
In conclusion, we generated recombinant attenuated NDVs that
express either the full length or soluble trimeric H5 protein.
Protective efficacy of NDV-HA, NDV-sH53 and sH53
protein against lethal HPAIV H5N1 infection in chickens
To examine the protective efficacy of NDV-sH53 compared to
NDV-H5, groups of 10 chickens were vaccinated oncewith a dose of
107 TCID50, either via the ON/IT or IM route. Three weeks later,
the chickens were challenged by inoculation with a lethal dose of
HPAIV H5N1. In parallel, as a control, one group of chickens was
vaccinated IM with Stimune-adjuvanted sH53 that had been
purified from the cell culture supernatant of NDV-sH53-infected
QM5 cells (Fig. 1D). As a challenge control, one group of chickens
received PBS. None of the chickens showed symptoms of disease
over the 3-week observation period after vaccination, in agreement
with the ICPI values determined for the recombinant NDVs lacking
the multibasic cleavage site (see above). The percentages of chickens
surviving the challenge and the mean clinical scores per group after
the challenge are shown in Fig. 2. All mock-vaccinated birds died
from the challenge within 2 days (Fig 2A), resulting in a clinical
index of 2.7 out of a possiblemaximumof 3.0 (Fig. 2B). Five out of 10
chickens that received NDV-H53 via the ON/IT route died within
2 days; of the 5 survivors, however, only one showed illness (a score
of 1 between day 7 and 10), resulting in an overall clinical index of
1.4. ON/IT delivery of NDV-H5 induced sufficient immunity to
protect 80% of the chickens (Fig. 2A), with one animal dying on day
6 and 8 each. None of the survivors showed clinical signs, resulting in
a clinical index of 0.3 (Fig. 2B). Vaccination of animals via the IM
route with NDV-sH53 provided complete protection; all chickens
survived without showing symptoms indicative of influenza-related
disease (Fig. 2C and D). Similar results were obtained when animals
were vaccinated IM with NDV-H5 or with adjuvanted sH53.
Antibody responses against NDV and AIV were measured in
individual serum samples collected immediately prior to challenge
(day 21) byHI assays. Effective induction ofNDVvector-specificHI
antibodies was observed after immunization with NDV-H5 and
NDV-sH53 (geometric means ranging between 243 and 521)
regardless of the route of administration used (Fig. 3A). Mock-
vaccinated chickens and chickens that received sH53 protein all had
a NDV-specific HI titer below the detection limit and were assigned
a value of 2, although these latter, but not the former, animals clearly
displayed AIV-specificHI titers (Fig. 3B). Following IMvaccination,
AIV-specific HI antibody titers in chickens that receivedNDV-sH53
ranged from a maximum of 192 to a minimum of 8 (mean titer of
55.4), comparable to those detected in NDV-H5 vaccinated birds
(mean titer of 38.7; Fig. 3B), which was apparently sufficient to
protect these birds against the lethal challenge. Essentially the same
antibody titers (mean titer of 28.2) could be detected after ON/IT
vaccination with NDV-H5, except in two chickens, both of which
had a titer of 6 or lower and did not survive the challenge. AfterON/
IT vaccination of animals with NDV-sH53, chickens that survived
the challenge had developed antibody levels within the same range
as the other protected animals (96-16), while no antibodies were
measurable in the chickens that died, resulting in a mean titer of
11.5. The results show that survival of vaccinated chickens
corresponds with the induction of HI titers of 8 or higher. While
all animals vaccinated with the recombinant NDVs reached
protective HI titers after IM immunization, ON/IT administration
was less effective, which was most apparent for the animals that
received NDV-sH53. As no NDV- or AIV-specific HI titers were
detected after IM immunization with UV-inactivated NDV, we
conclude that replication of NDV was required for the observed
immunogenicity (data not shown).
Shedding of challenge virus
To examine whether vaccination with recombinant NDVs
protected chickens from shedding challenge virus, tracheal and
cloacal swabs sampled from each chicken on day 2, 4 and 7
p.c. were pooled and tested for the presence of viral RNA using
a quantitative RT-PCR assay detecting the M1 gene. The
results are shown in Table 1. All chickens that were immunized
with NDV vector vaccine tested positive at day 2 and/or day 4
p.c., at least when they survived the challenge for that time
period. The birds, vaccinated with recombinant NDV vector
vaccine, that were protected against the lethal challenge did
not shed challenge virus at day 7 p.c., i.e. no viral RNA could
be detected in the swabs taken from these birds at that time
point. Of all the birds that received sH53, only two tested
positive for viral RNA in their swabs and only on day 2 p.c.
Notably, these two birds developed the lowest AIV-specific
antibody titers of the group (Fig. 3B). In conclusion, birds
vaccinated with NDV vector vaccine no longer shed virus at
day 7 p.c., although vaccination with the adjuvanted recom-
binant protein preparation appeared to be more effective in
diminishing virus shedding.
immunocytochemistry using mAb specific for NDV F or influenza virus H5. Scale bars represent 400 mm. C) Western blot analysis with an anti-H5 mAb
following SDS-PAGE of combined lysate of QM5 cells and the cell culture supernatant (20 ml/T75 flask). The MW of the marker proteins is indicated on
the left. D) The sH53 protein was purified from the supernatant of NDV-sH53-infected QM5 cells and subjected to SDS-PAGE (, 1 mg/15 ml), after
which proteins were stained with Blue stain reagent. A series of BSA dilutions were run in parallel. E) Blue native PAGE analysis of sH53 purified from
the cell culture supernatant of NDV-sH53-infected QM5 cells (, 1.7 mg/20 ml). The position in the gel of the trimeric and monomeric form of the H5
protein is indicated. Prior to gel electrophoresis some samples were heated at 95uC for the indicated time periods.
doi:10.1371/journal.pone.0044447.g001
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Protective efficacy of NDV-H5 and NDV-sH53 against
lethal HPAIV H5N1 infection in mice
The efficacy of NDV-sH53 and NDV-H5 vector vaccines was
also examined in mice. To this end, groups of 10 mice were
vaccinated ON or IM and challenged three weeks later with ,10
LD50 of HPAIV H5N1. The percentage of mice surviving the
infection, body weights and median clinical scores per group
observed after the challenge are shown in Fig. 4. The mock-
vaccinated mice, which all showed respiratory distress and
significant weight loss, died at day 7 or 8 p.c. Vaccination with
NDV-sH53 did not protect mice from a lethal challenge, regardless
of the route of vaccine administration. In both these groups, mice
started to lose weight soon after infection, which continued until
they died. Intramuscular vaccination with NDV-H5 also did not
protect mice against disease and concurrent weight loss; yet 30%
Figure 2. Vaccination of chickens. Groups of 10 SPF chickens were immunized with 107 TCID50 of NDV-H5 or NDV-sH5
3, either via the ON/IT or IM
route. Another group received an IM immunization with sH53 adjuvanted in Stimune. As a challenge control, one group of chickens was mock-
vaccinated with PBS. Three weeks after the vaccination, birds were challenged with ,105 TCID50 of HPAIV H5N1. A and B) Kaplan-Meier survival
curves indicating percentage of survival p.c. on each day for each group that was (mock-)vaccinated via the ON/IT (A) or IM (B) route. C and D) Clinical
index calculated on basis of clinical signs (as described in materials and methods) observed after challenge for each group that was (mock-
)vaccinated ON/IT (C) or IM (D). An index of 3.0 means that all birds died within 24 hours. For reference, each panel includes the same PBS group.
doi:10.1371/journal.pone.0044447.g002
Figure 3. Serum antibody responses in vaccinated chickens. HI antibody titers against A) NDV Herts/33 or B) AIV measured in individual
serum samples collected on day 21 p.v. via ON/IT or IM route. Titres are expressed as the reciprocal of the highest serum dilution showing HI. The
dashed line indicates the lower limit of detection. Titers below the detection limit were assigned a value of 2 or 4, respectively for calculation of the
mean. Horizontal bars represent the geometric mean titers of the groups and vertical bars represent 95% confidence intervals. Serum titers from
chickens that died after the challenge are indicated by filled circles, the open circles correspond to animals that survived the challenge. For reference,
each panel includes the same PBS group.
doi:10.1371/journal.pone.0044447.g003
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of the vaccinated animals survived. These animals lost weight
comparable to the control group until day 8 p.c., after which they
regained weight. At day 12 p.c. they appeared healthy again. In
contrast, ON administration of NDV-H5 conferred protection to
90% of the mice. This group showed only mild signs of disease (a
median score of 1) and only a limited decline (,10%) in body
weight. Strikingly, none of these survivors had HI antibodies
against NDV or AIV. In conclusion, while NDV-sH53 was unable
to protect mice against a lethal challenge with H5N1, protection
was observed after ON but not after IM vaccination with NDV-
H5.
Discussion
Once the epidemic of H5N1 HPAIV among poultry was
recognized as a potential threat to human health, policy makers,
vaccine manufacturers and researchers have joined forces to
develop convenient, safe, effective and cost-efficient vaccines
against HPAIV for poultry and humans. Because the use of live
influenza virus strains has safety restrictions, several alternatives
including heterologous live vector viruses expressing the influenza
H5 antigen are being explored. The use of recombinant lentogenic
NDV as vector vaccine against H5N1 is an attractive approach, as
vaccination of poultry with such viruses is expected to result in
protection both against infection with velogenic NDV and
HPAIV. However, the use of NDV live vector vaccines also raises
safety concerns as heterologous viral attachment and fusion
proteins may be incorporated into NDV virions as has been
demonstrated for HA of AIV [7,11,16]. An NDV vector
expressing HA in a soluble trimeric form that is released from
cells might offer a safe alternative, while retaining the advantages
of a live vaccine and of expression of a native HA antigen. In the
present study, we generated recombinant attenuated NDV
expressing either trimeric sH53 or full length H5 by reverse
genetics using the backbone of the Herts strain. The potential of
these NDV recombinants as live vaccine was studied by evaluating
their ability to protect chickens and mice against a lethal challenge
with H5N1 HPAIV. Although the protective efficacy of NDV
expressing full length H5 was generally greater than that of NDV
expressing sH53, chickens were fully protected against the lethal
challenge after a singly immunization with NDV-sH53 when
administered via the IM route.
Deletion of the multibasic cleavage site in the F protein of the
velogenic NDV strain Herts/33, resulted in an attenuated virus
that was subsequently used as a vector for vaccinating chickens
against HPAIV. IM or ON/IT immunization with such an
attenuated NDV expressing full length H5 protected 100% or
80% of the vaccinated chickens, respectively, against a lethal
challenge with HPAIV H5N1. Differences in protection levels
correlated with the observed AIV HI titers in the chicken sera.
Protected chickens did not shed the challenge virus at day 7 p.c.
Previous experiments, in which chickens were vaccinated with
NDV-HA recombinants based on attenuated NDV strains,
resulted in variable degrees of protection ranging from 40%
(immunization with NDV strain Hitchner B1 expressing H7 via
eye drop method) [10] to 90% (high-fusogenic NDV vector
expressing chimeric F-H7 applied by eye drop) [9] or 100% (ON
administration of NDV strain LaSota expressing H5) [5,11].
There are several factors which could explain the different results,
including differences in replication of the NDV strain, HA gene
insertion site, HA subtype, administration route, and the vaccine
or challenge dose used.
In the present study, chickens developed comparable levels of
HI antibody titers against NDV, regardless of the administration
route used, indicating that infection and spread of NDV-H5 in the
muscular tissue is not a limiting factor for an adequate immune
response. Although protection against NDV was not assessed, the
mean NDV HI titers were sufficiently high to assume that, with
reference to observations by Veits and coworkers [11], the
vaccinations would also have protected the chickens against
virulent NDV infection.
The protective efficacy of NDV expressing sH53 in chickens
proved to be as high as that of NDV expressing full length H5
when given via the IM route: all animals were protected, while
similar AIV HI titers were induced. In contrast, NDV-sH53
administered by the ON/IT route provided lower protection and
elicited lower AIV HI antibody titers than NDV-H5 delivered via
this route (50% vs 80%). The lower antibody levels may be the
consequence of a reduced amount of HA antigen exposed to the
immune system during NDV-sH53 infection of the respiratory
Table 1. Detection of H5N1 challenge virus in tracheal and cloacal swabs of vaccinated chickens.
ON/IT vaccinationa IM vaccination
NDV-H5 NDV-sH53 NDV-H5 NDV-sH53 sH53
Bird # D2 D4 D7 D2 D4 D7 D2 D4 D7 D2 D4 D7 D2 D4 D7
1 2.3 2 2 1.9 2 2 3.6 2 2 5.0 2 2 2 2 2
2 2 2.5 2 x x x 3.9 2.7 2 3.1 2 2 2 2 2
3 3.9 5.7 x 2.3 2 2 4.1 2 2 2 4.6 2 2 2 2
4 1.6 2 2 x x x 2 2 2 3.7 2.8 2 2 2 2
5 4.0 4.0 x x x x 3.3 2 2 3.3 2 2 2 2 2
6 2.8 3.5 2 x x x 4.6 2.9 2 2.8 2 2 1.6 2 2
7 2 4.4 2 x x x 4.2 2 2 2 1.2 2 2 2 2
8 4.4 4.0 2 2.7 2 2 3.2 4.5 2 2 2 2 4.2 2 2
9 2 1.6 2 1.8 2 2 3.5 1.8 2 2 1.8 2 2 2 2
10 2.6 3.4 2 2 2 2 3.6 5.3 2 2 5.8 2 2 2 2
aDay (D) post infection on which tracheal and cloacal swabs were collected are indicated. Amount of RNA detected in swabs is expressed as log10 TCID50 ml-1
equivalents.2= negative (CT .39.0); x = not tested because chicken did not survive after challenge with HPAIV H5N1.
doi:10.1371/journal.pone.0044447.t001
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tract, even though lentogenic NDV replicates most efficiently at
that site [38]. The soluble H5 proteins may very well be trapped
via their efficient binding to the a2-3-linked sialic acid receptors
[20,39] that are omnipresent in mucus and on the epithelial cells
lining the respiratory tract of chickens [40]. When trapped by its
interaction with sialic acid receptors, sH53 may be less immuno-
genic than as free trimer or as membrane-anchored, full length
HA. A similar difference in protective efficacy was observed after
vaccination of mice with our recombinant NDVs. The mouse
respiratory tract is also known to be rich in a2-3-linked sialic acid
[41,42], resulting in entrapment of recombinant soluble HA.
When this scenario is correct, introduction of point mutations that
abolish sialic acid-binding by HA [43] would be expected to
increase the protective efficacy of NDV-sH53. Alternatively, it has
been suggested that influenza viruses allow efficient cross-linking of
B cell receptors because they present HA molecules in a repetitive
array [44]. Such arrangement, which will also appear at the
membranes of NDV-H5 virions and possibly of cells infected with
NDV in the case of NDV-H5 but not of NDV-sH53, may result in
a better immune response. Differences in immunogenicity between
full length and soluble H5 are not likely to result from differences
in glycosylation as both immunogens carry the same number of N-
linked glycosylation sites.
While NDV-H5 effectively immunized chickens after adminis-
tration by the IM route, the mucosal immunization route was
clearly superior in mice. After a single ON dose with NDV-H5,
90% of the mice were protected against a lethal infection by
HPAIV H5N1, whereas none of the animals were protected after
IM administration. Unlike chickens, none of the mice developed
detectable levels of HA- or NDV specific antibodies after IM
immunization, which may be explained by inefficient replication
of NDV after IM administration. However, also after ON
vaccination, which resulted in protection of 90% of the mice for
NDV-H5, no HA- or NDV-specific antibodies were detectable in
serum. As mice vaccinated with NDV-sH53 were not protected at
all, an aspecific vector immunization effect can be excluded.
Apparently, the absence of serum antibodies does not necessarily
imply that the vaccine is ineffective. Likewise, mice [5] and
Figure 4. Vaccination of mice. Groups of 10 BALB/c mice were vaccinated with 106.5 TCID50 of NDV-H5 or NDV-sH5
3, either via the ON or IM route.
One group of mice was mock-vaccinated (PBS) as challenge control. Three weeks after the vaccination, mice were infected with ,10 LD50 of HPAIV
H5N1 and weighed daily and observed for clinical signs during 14 days. Graphed for each group are A and B) Kaplan-Meier survival curves indicating
percentage of survival p.c., C and D) mean percentage of body weight changes relative to starting weights measured on the day of challenge (day 0)
with error bars representing the standard deviation, and E and F) median clinical scores observed after challenge. For reference, each panel includes
the same PBS group.
doi:10.1371/journal.pone.0044447.g004
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primates [6], which had been vaccinated with a similar NDV-
vectored vaccine, displayed very low or no measurable serum HI
or neutralizing antibody titers to influenza virus. Protection despite
the lack of serum antibodies to AIV suggests that immunity in
these mice is mediated by a mucosal rather than a systemic
antibody response or antibody-independent (T-cell mediated)
immunity, which restrict replication of influenza virus in the
upper respiratory tract. It is has been shown that NDV is a very
efficient inductor of type I interferons, which promote antigen
presentation through the MHC class I pathway mediating
activation of CD8+ T-cells [45].
Our study showed, in agreement with other studies, that
attenuated NDV expressing full length HA is an attractive live
vaccine candidate to protect poultry and possibly also other
(mammalian) species against HPAIV. In addition, we investigated
the protective efficacy of recombinant NDV expressing soluble
trimeric HA proteins, thereby excluding the possibility of HA
incorporation into the NDV particle. Although a single adminis-
tration of NDV-sH53 vaccine by the IM route provided complete
protection against a lethal HPAIV H5N1 challenge in chickens
and was partially protective when administered ON/IT, this
vaccine candidate appeared less effective than NDV expressing full
length H5, which was most apparent in mice. Nevertheless, this
study provides proof of concept for the use of recombinant vector
vaccines expressing a soluble form of a heterologous viral
membrane protein. Such vectors may be advantageous as they
preclude the incorporation of heterologous membrane proteins
into the viral vector particles, which may result in the generation of
vaccine vectors with altered tropism and/or pathogenicity. In our
view, it will therefore be of interest to study the applicability of this
concept also for other vector-immunogen combinations.
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